Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | YTHDC1 | Q96MU7 | 3/20 | 0.34 |
| ▸ | YTHDF2 | Q9Y5A9 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20421353 | 0.70 | PRMT1 (0.37) | MAP4K4 | |
| SCHEMBL16834106 | 0.65 | KDM4E (0.33) | — | |
| SCHEMBL14567010 | 0.63 | YTHDC1 (0.48) | PDPK1YTHDC1YTHDF2MAP4K4 | |
| SCHEMBL5565969 | 0.63 | PDPK1 (0.45) | PDPK1YTHDC1YTHDF2MAP4K4 | |
| SCHEMBL1025250 | 0.60 | PDE10A (0.37) | — | |
| SCHEMBL14983681 | 0.58 | YTHDC1 (0.44) | PDPK1YTHDC1YTHDF2MAP4K4 | |
| SCHEMBL14782611 | 0.57 | PDPK1 (0.39) | PDPK1YTHDC1YTHDF2MAP4K4 | |
| SCHEMBL26349130 | 0.57 | PDPK1 (0.39) | PDPK1YTHDC1YTHDF2MAP4K4 | |
| SCHEMBL25762070 | 0.57 | PDPK1 (0.39) | PDPK1YTHDC1YTHDF2MAP4K4 | |
| SCHEMBL5565234 | 0.57 | PDPK1 (0.44) | PDPK1YTHDC1YTHDF2MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023219114-A1 | MRNA CAP ANALOG AND METHOD FOR PRODUCING SAME, METHOD FOR PRODUCING MRNA, AND KIT | ヤマサ醤油株式会社 | 2023-11-16 | — | — | WO | claimed |
| US-7351827-B2 | Substituted oxetanes, method of making, and method of use thereof | THE UNIVERSITY OF CONNECTICUT (US) | 2008-04-01 | — | — | US | claimed |
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | claimed |
| JP-2007512358-A | — | — | 2007-05-17 | — | — | JP | claimed |
| EP-1685127-A1 | HETEROCYCLYL-SUBSTITUTED OXETANES FOR THE TREATMENT OF PROLIFERATIVE OR INFECTIOUS DISEASES | The University of Connecticut (US) | 2006-08-02 | — | — | EP | claimed |
| EP-1625138-A2 | PROTECTED MONOMERS | Alnylam Pharmaceuticals Inc. (US) | 2006-02-15 | — | — | EP | claimed |
| US-20050215568-A1 | Substituted oxetanes, method of making, and method of use thereof | UNIVERSITY OF CONNECTICUT, THE | 2005-09-29 | — | — | US | claimed |
| WO-2005051944-A1 | HETEROCYCLYL-SUBSTITUTED OXETANES FOR THE TREATMENT OF PROLIFERATIVE OR INFECTIOUS DISEASES | UNIVERSITY OF CONNECTICUT (US) | 2005-06-09 | — | — | WO | claimed |
| WO-2004094345-A2 | PROTECTED MONOMERS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | claimed |
| WO-2023219114-A1 | MRNA CAP ANALOG AND METHOD FOR PRODUCING SAME, METHOD FOR PRODUCING MRNA, AND KIT | ヤマサ醤油株式会社 | 2023-11-16 | — | — | WO | disclosed |
| US-20220403377-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11530408-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11312957-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210254065-A1 | iRNA AGENTS WITH BIOCLEAVABLE TETHERS | ALNYLAM PHARMACEUTICALS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-5994361-A | ANTITUMOR, ANTICANCER AGENT | BIOCHEM PHARMA (CA) | 1999-11-30 | — | — | US | disclosed |
| US-5631259-A | PURINE BASE DERIVATIVES FOR NUCLEOSIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-05-20 | — | — | US | disclosed |
| EP-0766683-A1 | NOVEL SUBSTITUTED PURINYL DERIVATIVES WITH IMMUNOMODULATING ACTIVITY | BIOCHEM PHARMA INC (CA) | 1997-04-09 | — | — | EP | disclosed |
| WO-1995035297-A1 | NOVEL SUBSTITUTED PURINYL DERIVATIVES WITH IMMUNOMODULATING ACTIVITY | BIOCHEM PHARMA INC. (CA) | 1995-12-28 | — | — | WO | disclosed |
| EP-0521463-A2 | Substituted cyclic cycloalkyltriols, process, intermediates for their preparation and their use as antiviral and antiparasitic agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-01-07 | — | — | EP | disclosed |
| US-3935184-A | Synthetic polyoxin type nucleosides | SYNTEX (U.S.A.) INC. (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220403377-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | PDPK1 2827/4885YTHDC1 3421/4885YTHDF2 3307/4885 |
| US-20050215568-A1 | Substituted oxetanes, method of making, and method of use thereof | PNP, TYMP, DHPS | PDPK1 855/4885YTHDC1 706/4885YTHDF2 951/4885 |
| US-11530408-B2 | Therapeutic compositions | SNRPE, HNRNPH3, RNASE1 | PDPK1 3170/4885YTHDC1 1211/4885YTHDF2 1096/4885 |
| US-11312957-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | PDPK1 2827/4885YTHDC1 3421/4885YTHDF2 3307/4885 |
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | PDPK1 4540/4885YTHDC1 334/4885YTHDF2 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.